Q-omics provides the consensus-scored RN7SKP266 profile across patient tissues and cancer cell-line models. RN7SKP266 expression is associated with patient survival in 6 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, RN7SKP266 is differentially expressed in 1, with the highest sampling consensus in BRCA. Additionally, RN7SKP266 RNA expression shows 10,410 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight STAD, BRCA, and GBM as cancer lineages where RN7SKP266 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RN7SKP266 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RN7SKP266 survival associations across molecular data types. RN7SKP266 RNA expression shows survival associations in the most cancer types (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RN7SKP266 RNA expression–survival associations across cancer types. High RN7SKP266 expression shows unfavorable associations in STAD, LUSC, LUAD, ESCA, THCA and SARC. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify STAD as the clearest survival context for RN7SKP266 RNA expression.
This table summarizes RN7SKP266 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for RN7SKP266. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RN7SKP266 shows higher tumor expression in BRCA. The BRCA box plot shows higher RN7SKP266 RNA expression in tumor versus normal tissue (log2 FC = +0.086, t-test p = .025).
This table shows molecular features associated with RN7SKP266 in patient tissues and cancer cell lines. In patient samples, RN7SKP266 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
